Moderna, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Moderna, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $13.00M, a 333.33% increase year-over-year.
- Moderna, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $19.00M, a 850.00% increase year-over-year.
- Moderna, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $10.00M, a 233.33% increase year-over-year.
- Moderna, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $2.00M, a 0.00% change year-over-year.
- Moderna, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $17.00M, a 59.52% decline from fiscal 2024.
- Moderna, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $42.00M, a 68.00% increase from fiscal 2023.
- Moderna, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $25.00M, a 50.00% decline from fiscal 2022.
- Moderna, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $50.00M, a 55.36% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $13.00M 10-Q · filed 2026-07-31 | $44.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | $19.00M 10-Q · filed 2026-05-01 | $34.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | $10.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $17.00M 10-K · filed 2026-02-20 |
| 2025-09-30 | $2.00M 10-Q · filed 2025-11-06 | $10.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | $3.00M 10-Q · filed 2026-07-31 | $10.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | $2.00M 10-Q · filed 2026-05-01 | $29.00M derived: sum of 4 quarters · filed 2026-05-01 |
| 2024-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $42.00M 10-K · filed 2026-02-20 |
| 2024-09-30 | $2.00M 10-Q · filed 2025-11-06 | $45.00M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-06-30 | $22.00M 10-Q · filed 2025-08-01 | $49.00M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-03-31 | $15.00M 10-Q · filed 2025-05-01 | $31.00M derived: sum of 4 quarters · filed 2026-02-20 |
| 2023-12-31 | $6.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $25.00M 10-K · filed 2026-02-20 |
| 2023-09-30 | $6.00M 10-Q · filed 2024-11-07 | $38.00M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-06-30 | $4.00M 10-Q · filed 2024-08-01 | $43.00M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-03-31 | $9.00M 10-Q · filed 2024-05-02 | $47.00M derived: sum of 4 quarters · filed 2025-02-21 |
| 2022-12-31 | $19.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $50.00M 10-K · filed 2025-02-21 |
| 2022-09-30 | $11.00M 10-Q · filed 2023-11-03 | $52.00M derived: sum of 4 quarters · filed 2024-02-23 |
| 2022-06-30 | $8.00M 10-Q · filed 2023-08-03 | $73.00M derived: sum of 4 quarters · filed 2024-02-23 |
| 2022-03-31 | $12.00M 10-Q · filed 2023-05-04 | $96.00M derived: sum of 4 quarters · filed 2024-02-23 |
| 2021-12-31 | $21.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $112.00M 10-K · filed 2024-02-23 |
| 2021-09-30 | $32.00M 10-Q · filed 2022-11-03 | $137.00M derived: sum of 4 quarters · filed 2023-02-24 |
| 2021-06-30 | $31.00M 10-Q · filed 2022-08-03 | $132.00M derived: sum of 4 quarters · filed 2023-02-24 |
| 2021-03-31 | $28.00M 10-Q · filed 2022-05-04 | $179.00M derived: sum of 4 quarters · filed 2023-02-24 |
| 2020-12-31 | $46.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $179.00M 10-K · filed 2023-02-24 |
| 2020-09-30 | $27.00M 10-Q · filed 2021-11-04 | $161.46M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $78.00M 10-Q · filed 2021-08-05 | $150.01M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $28.00M 10-Q · filed 2021-05-06 | $75.94M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $28.46M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $48.00M 10-K · filed 2022-02-25 |
| 2019-09-30 | $15.55M 10-Q · filed 2020-10-30 | $20.61M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $3.93M 10-Q · filed 2020-08-06 | $5.34M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $57.00K 10-Q · filed 2020-05-07 | $1.46M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $1.43M 10-K · filed 2021-02-26 |
| 2018-09-30 | $290.00K 10-Q · filed 2019-11-06 | |
| 2018-06-30 | $48.00K 10-Q · filed 2019-08-08 | |
| 2018-03-31 | $22.00K 10-Q · filed 2019-05-09 | |
| 2017-12-31 | $212.00K 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |